Corbus Pharmaceuticals Holdings, Inc. - Common Stock, $0.0001 par value (CRBP)

CUSIP: 21833P301

Q4 2025 13F Holders as of 31 Dec 2025

Holder snapshot 7 signals
Share change
+4,456,111
Put/Call ratio
0%
SEC-reported price per share
$8.14
Number of holders
100
Value change
+$34,670,041
Number of buys
52
Open additional details 1 more signal available
Number of sells
30
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
17,685,185

Security key

21833P301

Report period

Q4 2025

Institutions

100

Top holders

10

Ownership snapshot

Top reported holders of CRBP - Corbus Pharmaceuticals Holdings, Inc. - Common Stock, $0.0001 par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Cormorant Asset Managemen...
Disclosed value leader
Cormorant Asset Managemen...
Comparable rows
15/15
Latest evidence
31 Dec 2025
13F 13D/G 3/4/5 Lead comparable stake: 13% 13D/G row: Cormorant Asset Management, LP Showing 1-6 of 15 holder rows.

Quick read

Cormorant Asset Management, LP leads the comparable SEC ownership view at 13%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Cormorant Asset Management, LP's linked filing trail.
Comparable ownership Top 5
Cormorant Asset Management, LP 13%
Aberdeen Group plc 7.5%
ORBIMED ADVISORS LLC 5.9%
CITADEL ADVISORS LLC 5.3%
VANGUARD GROUP INC 4.9%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Cormorant Asset Management, LP
13F 13D/G 3/4/5
Company · 10%+ Owner
13%
from 13D/G
$30,043,750
2,375,000 shares
30 Sep 2025
Aberdeen Group plc
13D/G 13F
Company
7.5%
$10,759,045
1,321,750 shares
$0 31 Dec 2025
ORBIMED ADVISORS LLC
13F 13D/G
Company · OrbiMed Capital LLC
5.9%
from 13D/G
$14,829,431
1,172,287 shares
30 Sep 2025
CITADEL ADVISORS LLC
13D/G
Kenneth Griffin
5.3%
$12,405,011
980,610 shares
$0 04 Nov 2025
VANGUARD GROUP INC
13F 13D/G
Company · The Vanguard Group
4.9%
from 13D/G
$7,742,180
612,030 shares
30 Sep 2025
BlackRock, Inc.
13F 13D/G
Company
2.9%
from 13D/G
$2,870,258
226,898 shares
30 Sep 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
100
Shares
13,244,299
Rows available
100
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2025 vs Q3 2025 Across Filers

Q3 2025 holders
79
Q4 2025 holders
100
Holder diff
21
Investor Q3 2025 Shares Q4 2025 Shares Share Diff Share Chg % Q3 2025 value Q4 2025 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .